[go: up one dir, main page]

MX2010009570A - Composiciones farmaceuticas que tienen una biodisponibilidad deseable. - Google Patents

Composiciones farmaceuticas que tienen una biodisponibilidad deseable.

Info

Publication number
MX2010009570A
MX2010009570A MX2010009570A MX2010009570A MX2010009570A MX 2010009570 A MX2010009570 A MX 2010009570A MX 2010009570 A MX2010009570 A MX 2010009570A MX 2010009570 A MX2010009570 A MX 2010009570A MX 2010009570 A MX2010009570 A MX 2010009570A
Authority
MX
Mexico
Prior art keywords
pharmaceutical compositions
compositions
therapeutic agent
desirable bioavailability
surfactant
Prior art date
Application number
MX2010009570A
Other languages
English (en)
Inventor
Bhagwati P Kabra
Nuria Carreras
Monica Cuchi
Francisco Javier Galan
Mridvika
Elena Gonzalez Puig
Nuria Jimenez
Carmen Martinez
Original Assignee
Alcon Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=41037889&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2010009570(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Alcon Res Ltd filed Critical Alcon Res Ltd
Publication of MX2010009570A publication Critical patent/MX2010009570A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/216—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acids having aromatic rings, e.g. benactizyne, clofibrate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

La presente invención está dirigida a la provisión de composiciones farmacéuticas. Las composiciones incluyen un agente terapéutico y una cantidad relativamente baja de surfactante para proporcionar una biodisponibilidad más alta del agente terapéutico. Las composiciones son particularmente deseables como composiciones oftálmicas en las cuales el agente terapéutico es una prostaglandina tal como travoprost y el surfactante es un aceite vegetal tal como aceite de ricino.
MX2010009570A 2008-03-17 2009-03-13 Composiciones farmaceuticas que tienen una biodisponibilidad deseable. MX2010009570A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US3711708P 2008-03-17 2008-03-17
US11192008P 2008-11-06 2008-11-06
PCT/US2009/037077 WO2009117316A2 (en) 2008-03-17 2009-03-13 Pharmaceutical compositions having desirable bioavailability

Publications (1)

Publication Number Publication Date
MX2010009570A true MX2010009570A (es) 2010-09-28

Family

ID=41037889

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010009570A MX2010009570A (es) 2008-03-17 2009-03-13 Composiciones farmaceuticas que tienen una biodisponibilidad deseable.

Country Status (24)

Country Link
US (5) US20090234004A1 (es)
EP (4) EP3042646B1 (es)
JP (2) JP5654444B2 (es)
KR (1) KR101586357B1 (es)
CN (2) CN105012964A (es)
AR (1) AR070888A1 (es)
AU (1) AU2009225824B2 (es)
BR (1) BRPI0908717B1 (es)
CA (1) CA2716994C (es)
CL (1) CL2009000624A1 (es)
DE (2) DE202009019114U1 (es)
DK (3) DK3042646T3 (es)
ES (3) ES2542728T3 (es)
HK (1) HK1212605A1 (es)
HU (1) HUE025619T2 (es)
MX (1) MX2010009570A (es)
PL (1) PL2265251T3 (es)
PT (1) PT2265251E (es)
RU (1) RU2503453C2 (es)
SI (1) SI2265251T1 (es)
TW (1) TWI544927B (es)
UY (1) UY31716A1 (es)
WO (1) WO2009117316A2 (es)
ZA (1) ZA201006227B (es)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2420223B1 (en) 2008-03-17 2017-07-19 Novartis Ag Aqueous pharmaceutical compositions containing borate-polyol complexes
TWI544927B (zh) 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
TWI489997B (zh) 2009-06-19 2015-07-01 Alcon Res Ltd 含有硼酸－多元醇錯合物之水性藥學組成物
CN103140215A (zh) * 2010-07-21 2013-06-05 爱尔康研究有限公司 具有提高的溶解度特征的药物组合物
EP2452669A1 (en) 2010-10-29 2012-05-16 Omnivision GmbH Ophthalmic composition
CA2914472C (en) * 2012-08-24 2019-09-03 Ashim K. Mitra Ophthalmic formulation of polyoxyl lipid or polyoxyl fatty acid and treatment of ocular conditions
ES2838756T3 (es) * 2014-01-24 2021-07-02 Sentiss Pharma Private Ltd Composición farmacéutica que comprende brinzolamida
EP2937076B1 (en) * 2014-04-25 2019-09-11 Alfred E. Tiefenbacher (GmbH & Co. KG) Eye drops containing prostaglandin and tyloxapol
EA201692402A1 (ru) * 2014-05-23 2017-03-31 Окьюлар Текнолоджис Сарл Лекарственные формы для местного применения и их использование
ES2954412T3 (es) * 2014-10-20 2023-11-22 Sentiss Pharma Private Ltd Solución oftálmica
US11458041B2 (en) 2015-10-08 2022-10-04 Ocular Therapeutix, Inc. Punctal plug and bioadhesives
PT3373976T (pt) 2015-11-10 2024-04-02 Sun Pharmaceutical Ind Ltd Formulações tópicas e suas utilizações
WO2017083410A1 (en) * 2015-11-12 2017-05-18 Ocular Technologies Sarl Topical formulations and uses thereof
RU2747455C2 (ru) 2016-02-29 2021-05-05 Сан Фарма Глобал Фзе Циклоспорин-содержащие лекарственные формы для наружного применения и их применения
CN115066232B (zh) 2020-02-06 2024-12-10 视尔普斯眼科公司 用于治疗眼病的组合物和方法
CA3177005A1 (en) 2020-04-27 2021-11-04 Michael Goldstein Methods of treating allergic conjunctivitis
TWI819317B (zh) * 2021-06-07 2023-10-21 溫士頓醫藥股份有限公司 含前列腺素衍生物的眼用奈米乳劑組合物

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3711708A (en) 1971-02-25 1973-01-16 Optical Coating Laboratory Inc Rapid scan identifier for use in infrared absorption spectroscopy
US3931319A (en) 1974-10-29 1976-01-06 Millmaster Onyx Corporation Capped polymers
US4027020A (en) 1974-10-29 1977-05-31 Millmaster Onyx Corporation Randomly terminated capped polymers
GB2084870B (en) 1980-10-10 1985-05-09 Muhlemann R Hans Oral compositions containing pyrimidine amine compounds and zinc salts
US4525346A (en) 1981-09-28 1985-06-25 Alcon Laboratories, Inc. Aqueous antimicrobial ophthalmic solutions
US4407791A (en) 1981-09-28 1983-10-04 Alcon Laboratories, Inc. Ophthalmic solutions
US4836986A (en) * 1984-09-28 1989-06-06 Bausch & Lomb Incorporated Disinfecting and preserving systems and methods of use
US5037647A (en) 1988-09-15 1991-08-06 Alcon Laboratories, Inc. Aqueous antimicrobial opthalmic solutions comprised of quaternary ammonium compound, citric acid, citrate and sodium chloride
US5145643A (en) 1990-01-05 1992-09-08 Allergan, Inc. Nonoxidative ophthalmic compositions and methods for preserving and using same
US5221664A (en) 1990-04-23 1993-06-22 Magainin Pharmaaceuticals Inc. Composition and treatment with biologically active peptides and toxic cations
SG49774A1 (en) 1990-12-27 1998-06-15 Allergan Inc Method and composition for disinfection contact lenses
US5932572A (en) * 1992-02-21 1999-08-03 Alcon Laboratories, Inc. Topical anti-glaucoma compositions
US5505953A (en) 1992-05-06 1996-04-09 Alcon Laboratories, Inc. Use of borate-polyol complexes in ophthalmic compositions
US5300287A (en) 1992-11-04 1994-04-05 Alcon Laboratories, Inc. Polymeric antimicrobials and their use in pharmaceutical compositions
US5320843A (en) 1992-12-10 1994-06-14 Polymer Technology Corporation Method for improving antibacterial properties of ophthalmic solutions
WO1996003158A1 (en) 1994-07-22 1996-02-08 Alcon Laboratories, Inc. Use of low molecular weight amino acids in ophthalmic compositions
US5603929A (en) * 1994-11-16 1997-02-18 Alcon Laboratories, Inc. Preserved ophthalmic drug compositions containing polymeric quaternary ammonium compounds
US6011062A (en) 1994-12-22 2000-01-04 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
US5631287A (en) 1994-12-22 1997-05-20 Alcon Laboratories, Inc. Storage-stable prostaglandin compositions
BR9607808A (pt) 1995-03-20 1998-07-07 Unilever Nv Composição para limpeza da pele e processo para realçar o efeito antimicrobiano das formulações para limpeza da pele
HU225329B1 (en) 1996-09-12 2006-09-28 Richter Gedeon Vegyeszet Use of zinc or cobalt hyaluronate associate for the manufacture of pharmaceutical compositions of antimicrobial activity
AU734789B2 (en) * 1996-11-01 2001-06-21 Alcon Laboratories, Inc. Use of a combination of carbonic anhydrease inhibitors and prostaglandins for treating glaucoma
GB9624928D0 (en) 1996-11-29 1997-01-15 Lintrend Developments Ni Ltd Fibrous products and their production
US6071904A (en) * 1996-12-11 2000-06-06 Alcon Laboratories, Inc. Process for manufacturing ophthalmic suspensions
CA2272308C (en) 1996-12-13 2007-01-16 Alcon Laboratories, Inc. Use of low molecular weight amino alcohols in ophthalmic compositions
AR002194A1 (es) * 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany Instrumento computarizado para el analisis del movimiento.
JP2002501533A (ja) * 1997-05-30 2002-01-15 メルク エンド カンパニー インコーポレーテッド 高眼圧症治療のための眼科用組成物
US6235781B1 (en) * 1998-07-14 2001-05-22 Alcon Laboratories, Inc. Prostaglandin product
PT1011728E (pt) * 1998-07-14 2005-03-31 Alcon Mfg Ltd Recipientes de polipropileno para produtos de prostaglandina
US6034043A (en) 1999-04-20 2000-03-07 Lever Brothers Company, Division Of Conopco, Inc. Mild antimicrobial liquid cleansing formulations comprising polyvalent cation or cations for improving an antimicrobial effectiveness
US6482799B1 (en) 1999-05-25 2002-11-19 The Regents Of The University Of California Self-preserving multipurpose ophthalmic solutions incorporating a polypeptide antimicrobial
US20020009507A1 (en) 2000-01-19 2002-01-24 Alcon Universal Ltd. Use of polyethoxylated castor oil for the treatment of dry eye
WO2002022131A1 (fr) * 2000-09-13 2002-03-21 Santen Pharmaceutical Co., Ltd. Collyre
CA2430127C (en) 2000-11-29 2010-04-20 Novartis Ag Aqueous disinfecting system comprising a microbicide and 1,3-bis(tris[hydroxymethyl]methylamino)propane
JP2002332225A (ja) * 2001-05-09 2002-11-22 Lion Corp 眼科用組成物
DE10222388A1 (de) * 2001-05-22 2003-02-13 Denso Corp Kompressor mit veränderbarer Verdrängung
US6743439B1 (en) * 2001-06-27 2004-06-01 Alcon, Inc. Ophthalmic compositions containing copolymers of sulfonated styrene and maleic anhydride
JP4863589B2 (ja) 2001-09-28 2012-01-25 ロート製薬株式会社 水性組成物
KR20050057251A (ko) * 2002-09-09 2005-06-16 산텐 세이야꾸 가부시키가이샤 라타노프로스트를 유효 성분으로 하는 투명한 점안액
US7074827B2 (en) * 2002-10-24 2006-07-11 Sucampo Ag (Usa) Inc. Method for treating ocular hypertension and glaucoma
US20060199863A1 (en) 2003-07-31 2006-09-07 Santen Pharmaceutical Co., Ltd. Product containing prostaglandin
JP4453815B2 (ja) * 2003-12-08 2010-04-21 ライオン株式会社 ドライアイ治療剤
JP2005247801A (ja) * 2004-03-08 2005-09-15 Zeria Pharmaceut Co Ltd 安定な点眼剤
CN1946453A (zh) 2004-04-23 2007-04-11 米斯提克医药有限公司 多倍剂量药品配给系统
GB0501192D0 (en) 2005-01-20 2005-03-02 Resolution Chemicals Ltd Stable prostaglandin-containing compositions
US7851504B2 (en) 2005-03-16 2010-12-14 Allergan, Inc. Enhanced bimatoprost ophthalmic solution
JP5394927B2 (ja) 2006-09-28 2014-01-22 アルコン リサーチ， リミテッド 自己保存性水性医薬品組成物
WO2008052031A2 (en) 2006-10-24 2008-05-02 Alcon Research, Ltd. 2-pyrrolidone derivatives for preservation of ophthalmic, otic and nasal compositions
US20080093247A1 (en) * 2006-10-24 2008-04-24 Alcon Manufacturing Ltd. Packaging materials for formulations containing 2-pyrrolidone derivatives
US20100120908A1 (en) * 2007-02-07 2010-05-13 Teika Pharmaceutical Co., Ltd Eye drop preparation comprising latanoprost
TWI544927B (zh) * 2008-03-17 2016-08-11 愛爾康研究有限公司 具有低濃度的表面活性劑以促進治療劑之生物可利用性的藥學組成物
EP2127638A1 (en) 2008-05-30 2009-12-02 Santen Pharmaceutical Co., Ltd Method and composition for treating ocular hypertension and glaucoma
EP4512277A3 (en) 2019-05-31 2025-04-30 Karsten Manufacturing Corporation Golf bag convertible strap assembly

Also Published As

Publication number Publication date
CA2716994A1 (en) 2009-09-24
HUE025619T2 (en) 2016-04-28
UY31716A1 (es) 2009-08-31
CA2716994C (en) 2013-05-28
EP2599475B1 (en) 2017-04-26
US20120029073A1 (en) 2012-02-02
EP2599475A2 (en) 2013-06-05
EP2265251B1 (en) 2015-05-27
JP2014012744A (ja) 2014-01-23
ZA201006227B (en) 2012-02-29
AU2009225824A1 (en) 2009-09-24
PL2265251T3 (pl) 2015-10-30
BRPI0908717B1 (pt) 2021-12-21
BRPI0908717A2 (pt) 2020-12-01
AR070888A1 (es) 2010-05-12
US20090234004A1 (en) 2009-09-17
SI2265251T1 (sl) 2015-08-31
US20090234013A1 (en) 2009-09-17
EP2705836A1 (en) 2014-03-12
TW200940068A (en) 2009-10-01
US8754123B2 (en) 2014-06-17
US8722735B2 (en) 2014-05-13
CN105012964A (zh) 2015-11-04
JP5654444B2 (ja) 2015-01-14
JP2011514384A (ja) 2011-05-06
DE202009019114U1 (de) 2016-08-01
DK2265251T3 (en) 2015-06-29
DE202009019087U1 (de) 2016-05-20
CL2009000624A1 (es) 2010-01-04
KR101586357B1 (ko) 2016-01-18
AU2009225824B2 (en) 2014-04-10
US8178582B2 (en) 2012-05-15
RU2503453C2 (ru) 2014-01-10
US20120245227A1 (en) 2012-09-27
KR20110005801A (ko) 2011-01-19
EP3042646B1 (en) 2017-05-10
WO2009117316A2 (en) 2009-09-24
RU2010142307A (ru) 2012-04-27
DK2599475T3 (en) 2017-08-21
US20140243409A1 (en) 2014-08-28
EP2265251A2 (en) 2010-12-29
HK1212605A1 (zh) 2016-06-17
DK3042646T3 (en) 2017-08-28
US9144561B2 (en) 2015-09-29
PT2265251E (pt) 2015-09-01
ES2635197T3 (es) 2017-10-02
ES2637028T3 (es) 2017-10-10
HK1220378A1 (en) 2017-05-05
CN101977588A (zh) 2011-02-16
WO2009117316A3 (en) 2010-09-10
EP2599475A3 (en) 2013-08-21
TWI544927B (zh) 2016-08-11
EP3042646A1 (en) 2016-07-13
ES2542728T3 (es) 2015-08-10

Similar Documents

Publication Publication Date Title
MX2010009570A (es) Composiciones farmaceuticas que tienen una biodisponibilidad deseable.
PH12016500216B1 (en) Stable pharmaceutical composition and methods of using same
WO2009087242A3 (en) Compositions comprising trans-tert-butyl cyclohexanol as skin irritation-reducing agent
NZ618734A (en) Polyunsaturated fatty acids for the treatment of diseases related to cardiovascular, metabolic and inflammatory disease areas
CA2871471C (en) Dna-pk inhibitors
IN2012DN06581A (es)
JO2761B1 (en) Derivatives of alcohols 1-phenyl-2-pyridinealkyl as inhibitors
MX361618B (es) Formulaciones farmacéuticas que comprenden derivados de nitrocatecol y métodos para hacer las mismas.
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
CA2818187C (en) Bromodomain inhibitors and uses thereof
EA202091303A3 (ru) Композиция ингибитора jak для местного применения
WO2009118107A3 (de) Hautpflege-zusammensetzung
PH12012502159A1 (en) Pharmaceutical compositions and methods of making same
EP3626253A3 (en) Stable formulations of linaclotide
PH12014500179A1 (en) Fixed dose combination of bimatoprost and brimonidine
WO2011006935A3 (en) Tetrazole derivatives
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
WO2013057013A3 (en) Derivatives of 1-phenyl-2-pyridinyl alkyl alcohols as phosphodiesterase inhibitors
NZ708821A (en) Lfa-1 inhibitor formulations
TN2013000386A1 (en) Suspension type topical formulations comprising cyclic depsipeptide
WO2009109501A3 (en) Ocular pharmaceutical compositions
MX339361B (es) Derivados de alternano.
WO2013124700A3 (en) Composition based on silybum marianum seed oil and process for the preparation of the seed oil
WO2011041634A8 (en) Pyrazole inhibitors of phosphatidylinositol 3-kinase
MX2012005447A (es) Combinacion farmacéutica de compuesto de prostaglandina y nsaid (medicamentos antiinflamantorios no esteroideos) para el tratamiento de glaucoma e hipertensión ocular.

Legal Events

Date Code Title Description
FG Grant or registration